Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage IIIA)
- Ivan Bačić
- Robert Karlo
- Ana Šoštarić Zadro
- Zvonko Zadro
- Neven Skitarelić
- Anko Antabak
Published online on: December 8, 2017
Copyright: © Bačić et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
The aim of the present study was to evaluate angiogenesis by determining the micro vascular density (MVD) and the expression of vascular endothelial growth factor (VEGF‑A) in advanced non‑small cell lung cancer (NSCLC) tumor samples, and to analyze their associations with clinical parameters and survival. Tumor tissue specimens of fifty patients (41 males and 9 females), who underwent radical surgical treatment for NSCLC in stage IIIA (T1‑3N2) were collected for immunohistochemical analysis. MVD evaluation was performed using an anti‑CD31 monoclonal antibody and VEGF‑A expression using a polyclonal anti‑VEGF‑A antibody. The results were associated with two‑year survival. Statistical analysis revealed significant associations in the level of angiogenesis (high MVD) and shorter survival of patients with NSCLC (P=0.0007). VEGF‑A expression showed no association with micro vascular density (P=0.51) or survival (P=0.68). There was no significant association between MVD and VEGF‑A. The measurable, clinical MVD parameters could be used as a reliable prognostic factor for the survival of patients with advanced NSCLC.